Member Info for WeTookPelham

Think someone has already mentioned this, but another example of the increased high level(?) media exposure:

https://www.wsj.com/articles/scancell-ceo-hails-exciting-high-response-rate-to-melanoma-treatment-e913cd96

Bravo gf123, great post.

I'm not sure if you want to include 'hitman for hire' buttcrack in your CON list.

"...and yet another subtle de-ramp by Crumbs"

Exactly.

Crumbs, I think it's fair to say whatever you post now is taken with huge amount of salt. A tarnished reputation perhaps.

I said at the time, the motive behind anyone's post is as important as what's written in the actual post.

I just feel sorry for those that were panicked into selling, wether they interpreted the posts correctly or not, plus the likes of crackin trying to additionally stir the pot/kick the share price when it was down.

Https://www.linkedin.com/pulse/bracing-impact-bms-faces-steepest-patent-cliff-history-paul-shaw

...to add to inanacos and my post yesterday, how can BMS not be interested?

"20/9/2023

07:11 inanaco: i don't think folks have fully comprehended the significance and opportunity that this gives to the immunobody platform

Lindy is a diamond .....

Read Full ThreadFollowReply

20/9/2023

07:02 inanaco: just remember keytruda ... is linking arms with moderna to create the competitive advantage

but its short lived as i feel vaccines like scib1 will reduce market share considerably against personalised vaccine but a market will still exist .....

but can moditope break that market ? those that fail iscib1 ..... and could potentially be given a personal vaccine .... instead be given a moditope combo ?

fascinating to finally see what cutting edge vaccines can achieve

and surely Big Pharma must now look at the Covid vaccine

Read Full ThreadFollowReply

20/9/2023

06:35 inanaco: something Lindy said about patient numbers ............

because the efficacy is so high we don't need as many patients to prove up the data

that would also apply to the registrational trial

jt may be possible that Scancell could go it alone ...

however i suspect Bristol Myers to be very interested in bringing the treatment in house as they also have new products entering the market that would also have synergy

interesting times ......... but patient numbers go down on trial to achieve statistical evidence .... value increases

and we are talking big numbers,"

Agree, odd it's barely moved one way or another from around 20-23% most of the day.

...just an observation 🥸

Has someone got a link to the replay?

LD "...the data is so strong"

Just to add, you'd think there has already been some "courting" if you will, RE big pharma? So will be a case of now "we're all set, let's go"?

Were they waiting for the new business development officer (and CFO) to be in place before announcing today's data I wonder?

Yes exactly Dracula, the question is how long dare big pharma wait.

Data is now out, deal makers in place, conferences booked.

"Tumour reduction at 37 weeks.. 87% to 94%"

This needs re-emphasising/reiterating as much as possible IMO.

IMO we cannot also forget the all important 'Patent cliffs' that the big pharma are facing and need to tackle ASAP.

...Bristol-Myers Squibb(?) have been/are paying very very close attention to these results?

"...Anyway, don't want to get into personal spats, just enjoying this morning's ride...."

This. Apologies for distracting. Could hopefully be a crackin day/few days ahead.

Purely IMO, this doesn't feel like the usual pre conference hype run?

"...

In fairness, crackin called it right as it turned out."

I knew you'd say that, so very predictable RR. You weren't to know that, only in hindsight would you know.

So derampers get the benefit of the doubt but rampers don't?

Yeah... ok, we all understand your point of view.

This is not the usual start to a Monday morning ,that's for sure!